Thursday, September 22, 2016

Glucophage XR


See also: Generic Glucophage


Glucophage XR is a brand name of metformin, approved by the FDA in the following formulation(s):


GLUCOPHAGE XR (metformin hydrochloride - tablet, extended release; oral)



  • Manufacturer: BRISTOL MYERS SQUIBB

    Approval date: October 13, 2000

    Strength(s): 500MG [AB1]


  • Manufacturer: BRISTOL MYERS SQUIBB

    Approval date: April 11, 2003

    Strength(s): 750MG [RLD][AB]

Has a generic version of Glucophage XR been approved?


A generic version of Glucophage XR has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Glucophage XR and have been approved by the FDA:


metformin hydrochloride tablet, extended release; oral



  • Manufacturer: ALVOGEN

    Approval date: April 17, 2008

    Strength(s): 500MG [AB1], 750MG [AB]


  • Manufacturer: AMNEAL PHARMS NY

    Approval date: January 3, 2008

    Strength(s): 500MG [AB1], 750MG [AB]


  • Manufacturer: APOTEX

    Approval date: December 14, 2004

    Strength(s): 500MG [AB1]


  • Manufacturer: APOTEX

    Approval date: December 29, 2005

    Strength(s): 750MG [AB]


  • Manufacturer: BARR

    Approval date: October 14, 2004

    Strength(s): 750MG [AB]


  • Manufacturer: IMPAX LABS

    Approval date: July 30, 2004

    Strength(s): 500MG [AB1]


  • Manufacturer: IMPAX LABS

    Approval date: September 13, 2005

    Strength(s): 750MG [AB]


  • Manufacturer: INVENTIA HLTHCARE

    Approval date: January 18, 2012

    Strength(s): 500MG [AB1]


  • Manufacturer: MYLAN

    Approval date: September 8, 2005

    Strength(s): 750MG [AB]


  • Manufacturer: MYLAN

    Approval date: September 13, 2005

    Strength(s): 500MG [AB1]


  • Manufacturer: NOSTRUM

    Approval date: July 26, 2006

    Strength(s): 500MG [AB1]


  • Manufacturer: RANBAXY

    Approval date: June 29, 2005

    Strength(s): 750MG [AB]


  • Manufacturer: RANBAXY LABS LTD

    Approval date: June 18, 2004

    Strength(s): 500MG [AB1]


  • Manufacturer: SANDOZ

    Approval date: December 14, 2004

    Strength(s): 500MG [AB1]


  • Manufacturer: SUN PHARM INDS (IN)

    Approval date: February 9, 2006

    Strength(s): 500MG [AB1], 750MG [AB]


  • Manufacturer: TEVA

    Approval date: June 18, 2004

    Strength(s): 500MG [AB1]


  • Manufacturer: TEVA

    Approval date: April 12, 2005

    Strength(s): 750MG [AB]


  • Manufacturer: TORRENT PHARM

    Approval date: December 30, 2009

    Strength(s): 500MG [AB1]


  • Manufacturer: TORRENT PHARMS

    Approval date: February 18, 2010

    Strength(s): 750MG [AB]


  • Manufacturer: WATSON LABS FLORIDA

    Approval date: June 16, 2004

    Strength(s): 500MG [AB1]


  • Manufacturer: WATSON LABS FLORIDA

    Approval date: April 12, 2005

    Strength(s): 750MG [AB]


  • Manufacturer: WATSON LABS INC

    Approval date: December 14, 2004

    Strength(s): 500MG [AB1]


  • Manufacturer: ZYDUS PHARMS USA

    Approval date: April 20, 2005

    Strength(s): 500MG [AB1]


  • Manufacturer: ZYDUS PHARMS USA

    Approval date: April 21, 2005

    Strength(s): 750MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Glucophage XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Biphasic controlled release delivery system for high solubility pharmaceuticals and method
    Patent 6,475,521
    Issued: November 5, 2002
    Inventor(s): Peter; Timmins & Andrew B.; Dennis & Kiren A.; Vyas
    Assignee(s): Bristol-Myers Squibb Co.
    A biphasic controlled release delivery system for pharmaceuticals which have high water solubility, such as the antidiabetic metformin HCl salt, is provided which provides a dosage form that has prolonged gastric residence so that a dosing regimen of at least one gram metformin, once daily, may be achieved while providing effective control of plasma glucose. The delivery system includes (1) an inner solid particulate phase formed of substantially uniform granules containing a pharmaceutical having a high water solubility, and one or more hydrophilic polymers, one or more hydrophobic polymers and/or one or more hydrophobic materials such as one or more waxes, fatty alcohols and/or fatty acid esters, and (2) an outer solid continuous phase in which the above granules of inner solid particulate phase are embedded and dispersed throughout, the outer solid continuous phase including one or more hydrophilic polymers, one or more hydrophobic polymers and/or one or more hydrophobic materials such as one or more waxes, fatty alcohols and/or fatty acid esters, which may be compressed into tablets or filled into capsules. Methods for forming the so-described biphasic controlled release delivery system and using such biphasic controlled release delivery system for treating diabetes are also provided.
    Patent expiration dates:

    • March 19, 2018




  • Method of use of a biphasic controlled release delivery system for high solubility pharmaceuticals and method
    Patent 6,660,300
    Issued: December 9, 2003
    Inventor(s): Peter; Timmins & Andrew B.; Dennis & Kiren A.; Vyas
    Assignee(s): Bristol-Myers Squibb Co.
    A biphasic controlled release delivery system for pharmaceuticals which have high water solubility, such as the antidiabetic metformin HCl salt, is provided which provides a dosage form that has prolonged gastric residence so that a dosing regimen of at least one gram metformin, once daily, may be achieved while providing effective control of plasma glucose. The delivery system includes (1) an inner solid particulate phase formed of substantially uniform granules containing a pharmaceutical having a high water solubility, and one or more hydrophilic polymers, one or more hydrophobic polymers and/or one or more hydrophobic materials such as one or more waxes, fatty alcohols and/or fatty acid esters, and (2) an outer solid continuous phase in which the above granules of inner solid particulate phase are embedded and dispersed throughout, the outer solid continuous phase including one or more hydrophobic polymers, one or more hydrophobic polymers and/or one or more hydrophobic materials such as one or more waxes, fatty alcohols and/or fatty acid esters, which may be compressed into tablets or filled into capsules. Methods for forming the so-described biphasic controlled release delivery system and using such biphasic controlled release delivery system for treating diabetes are also provided.
    Patent expiration dates:

    • March 19, 2018
      ✓ 
      Patent use: METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION



See also...

  • Glucophage XR Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Glucophage XR Consumer Information (Cerner Multum)
  • Glucophage XR Advanced Consumer Information (Micromedex)
  • Metformin Consumer Information (Drugs.com)
  • Metformin Consumer Information (Wolters Kluwer)
  • Metformin Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Metformin Solution Consumer Information (Wolters Kluwer)
  • Metformin Consumer Information (Cerner Multum)
  • Metformin Advanced Consumer Information (Micromedex)
  • Metformin Hydrochloride AHFS DI Monographs (ASHP)
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)